ID   U-2940
AC   CVCL_1897
SY   U2940
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473453
DR   cancercelllines; CVCL_1897
DR   ChEMBL-Cells; CHEMBL4523523
DR   ChEMBL-Targets; CHEMBL4523554
DR   Cosmic; 2437272
DR   Cosmic; 2479246
DR   DepMap; ACH-001678
DR   DSMZ; ACC-634
DR   DSMZCellDive; ACC-634
DR   GEO; GSM1374972
DR   GEO; GSM1897963
DR   Lonza; 1539
DR   Progenetix; CVCL_1897
DR   PubChem_Cell_line; CVCL_1897
DR   Wikidata; Q54973561
RX   PubMed=16106419;
RX   PubMed=27566572;
RX   PubMed=28196595;
RX   PubMed=29533902;
RX   PubMed=31160637;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572).
CC   Doubling time: ~50 hours (DSMZ=ACC-634).
CC   HLA typing: A*02:01:01,02:01:01; B*07:02:01,07:02:01; C*07:02:01,07:02:01; DPA1*02:06,02:06; DQA1*01:02:01,01:02:01; DQB1*06:02:01,06:02:01; DRA*01:02:03,01:02:03; DRB1*15:01:01,15:01:01 (DSMZCellDive=ACC-634).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Donor information: Originally the patient was suffering from Hodgkin lymphoma.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): DSMZ=ACC-634
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,10
ST   D16S539: 10,12
ST   D18S51: 12,17
ST   D19S433: 14,15
ST   D21S11: 29
ST   D2S1338: 19
ST   D3S1358: 16,17
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   D8S1179: 12
ST   FGA: 24,26
ST   Penta D: 14,15
ST   Penta E: 7,14
ST   TH01: 7,9.3
ST   TPOX: 8,12
ST   vWA: 17
DI   NCIt; C8851; Diffuse large B-cell lymphoma
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   18Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 25
//
RX   PubMed=16106419; DOI=10.1002/ijc.21417;
RA   Sambade C., Berglund M., Lagercrantz S., Sallstrom J., Reis R.M.,
RA   Enblad G., Glimelius B., Sundstrom C.;
RT   "U-2940, a human B-cell line derived from a diffuse large cell
RT   lymphoma sequential to Hodgkin lymphoma.";
RL   Int. J. Cancer 118:555-563(2006).
//
RX   PubMed=27566572; DOI=10.18632/oncotarget.11524;
RA   Quentmeier H., Pommerenke C., Ammerpohl O., Geffers R., Hauer V.,
RA   MacLeod R.A.F., Nagel S., Romani J., Rosati E., Rosen A., Uphoff C.C.,
RA   Zaborski M., Drexler H.G.;
RT   "Subclones in B-lymphoma cell lines: isogenic models for the study of
RT   gene regulation.";
RL   Oncotarget 7:63456-63465(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//